POM-V Prescription Required

Kexxtone 32.4g Continuous-Release Intraruminal Device for Cattle

Active ingredient: Monensin

Form

Continuous-release intraruminal device

Species

Cattle

Manufacturer

Elanco GmbH

VMD MA No.

52127/5032

What it's used for

For the reduction in the incidence of ketosis in the peri-parturient dairy cow/heifer which is expected to develop ketosis.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Monensin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Kexxtone 32.4g Continuous-Release Intraruminal Device for Cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

For the reduction in the incidence of ketosis in the peri-parturient dairy cow/heifer
which is expected to develop ketosis.

Intraruminal use.
A single intraruminal device is to be administered to a dairy cow/heifer 3-4 weeks prior
to expected calving, using an appropriate administration tool.
Kexxtone delivers an approximate average dose of 335 mg of monensin per day for
approximately 95 days.
Follow instructions carefully.
Adequate animal restraint is required to properly administer this intraruminal device.
Such restraint must limit forward/backward motion and allow the animal’s head to
be held in the forward extended position and without pressure on the neck to prevent
choking.
1. Each intraruminal device has an individual number along the device body.
This should be recorded with the corresponding animal identification
number so that, should an intraruminal device be regurgitated, the animal
can be identified.
2. Fold wings down along the intraruminal device body and insert the device
into an appropriate administration tool, orifice end first.
3. Restrain the animal with its head and neck stretched forward. Grasp the
animal with one hand in the corner of the animal’s mouth. Introduce the
administration tool into the mouth avoiding the front teeth. In order to avoid
trauma and damage to the pharynx and oesophagus, do not use excessive
force.
4. Insert the administration tool past the base of the tongue making sure to
avoid the molar teeth. As the animal swallows, the administration tool will
move easily over the base of the tongue. DO NOT USE EXCESSIVE
FORCE. If resistance is encountered, withdraw the tool slightly and repeat
the procedure.
5. Be sure the head of the administration tool is past the base of the tongue.
When the animal swallows, eject the intraruminal device from the
administration tool.

Revised: May 2024
AN: 03448/2023

Do not use in animals weighing less than 300 kg bodyweight.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

In rare cases, digestive signs (e.g. diarrhoea, ruminant stomach disorder) have been
observed.
In very rare cases, oesophagus obstruction has been observed.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

Revised: May 2024
AN: 03448/2023
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated
reports).

Identification of animals for treatment should be at veterinary discretion. Risk factors
may include a history of energy-deficiency-related diseases, high body condition
score and parity.

In the event of early regurgitation, identify the animal by matching the animal ID
number with the number on the intraruminal device and re-administer an undamaged
intraruminal device (See section 4.5).

Revised: May 2024
AN: 03448/2023

Special precautions for use in animals
Hold treated cattle in a confined area for 1 hour after administration to observe for
failure to swallow or regurgitation. If this occurs re-administer the intraruminal device
if undamaged. If damaged, administer a new intraruminal device. Recheck cattle for
up to 4 days after dosing to observe for signs of an intraruminal device lodging in the
oesophagus.
Signs of lodging may include bloat which may be followed by coughing, drooling,
inappetence and unthriftiness.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Exposure to the active substance may elicit an allergic response in susceptible
individuals. People with known hypersensitivity to monensin or any of the excipients
should avoid contact with the veterinary medicinal product.
Do not eat, drink or smoke when handling the veterinary medicinal product.
Use gloves when handling an intraruminal device, including during retrieval of a
regurgitated intraruminal device.
Remove gloves and wash hands and exposed skin after handling intraruminal
devices.
Other precautions
Ingestion or oral exposure to monensin can be fatal in dogs, horses, other equines or
guinea fowl. Do not allow dogs, horses, other equines or guinea fowl access to
veterinary medicinal products containing monensin.
Due to the risk of bolus regurgitation, do not allow these species access to areas
where treated cattle have been kept.
Keep dogs away from treated animals. Accidental ingestion of active ingredient by
dogs has resulted in fatal consequences. In case of suspected ingestion by dogs,
seek veterinary advice immediately.

None known.

Keep the foil tightly closed.

Each intraruminal device contains 12 subunits each containing 2.7 g monensin
(equivalent to 2.9 g monensin sodium).
For the full list of excipients, see section

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.